コバヤシ　ヒロヒト   Kobayashi Hirohito   小林　博人    所属   医学部 医学科（附属足立医療センター）    職種   准教授
論文種別	総説
言語種別	英語
査読の有無	査読あり
招待の有無	招待あり
表題	γδ T Cell Immunotherapy-A Review.
掲載誌名	正式名：Pharmaceuticals (Basel, Switzerland) 略　 称：Pharmaceuticals (Basel) ISSNコード：14248247/14248247
掲載区分	国外
巻・号・頁	8(1),pp.40-61
著者・共著者	Kobayashi Hirohito, Tanaka Yoshimasa
発行年月	2015/02
概要	Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy.
DOI	10.3390/ph8010040
PMID	25686210